Kuehne+Nagel has entered into a long-term agreement for a new airside facility strategically located in the airport zone of OR Tambo International airport, Johannesburg, South Africa – the largest and busiest airport in Africa. As part of this agreement, Kuehne+Nagel offers customers a set of logistics solutions, including warehousing, transportation, customs brokerage, supply chain management, and airside support to project-specific charter in- and outbound shipments. Core to this offering is a comprehensive cold chain solution, ensuring around-the-clock temperature-control to safeguard the integrity of highly sensitive pharma products.

The new offering is pivotal to supporting Africa’s aim to become more self-reliant in healthcare operations. South Africa, Nigeria, and Algeria are leading the manufacturing charge in sub-Saharan Africa, while imports from Europe, North America, India and China remain crucial to meeting Africa’s demand for medicines and basic healthcare. To support its healthcare customers – both importers and manufacturers – in executing their strategic growth plans for Africa, Kuehne+Nagel’s new facility is designed with healthcare and pharmaceuticals in mind.

“Pharmaceuticals in particular are highly-sensitive, time-critical products,” says Gereon Niemeier, Managing Director, Kuehne+Nagel South Africa. “Every minute these products spend on the tarmac exposes them to temperature fluctuations, physical damage, and loss. Our new facility addresses all these challenges to ensure product stability throughout the journey.”

“Our people have the expertise for plane-side access that other logistics providers don’t,” Niemeier points out. “In addition, the facility is so close to the charter parking area that we can provide in-person visibility resources, as well as a unique dollie solution, that greatly reduce the risk of ground handling errors as well as shipment claims. On-site monitoring protects product stability — whether temperature-controlled, high value or time critical — throughout the entire journey.

Amedisys, Inc., a leading provider of quality home health, hospice, personal care and high-acuity care, has closed on its joint venture with the University of Arkansas for Medical Sciences (UAMS) to provide home health services in Searcy and Little Rock.

This joint venture is part of the partnership between UAMS, Amedisys and Contessa, an Amedisys company, to offer patients a full spectrum of medical care in the comfort and convenience of their own homes through UAMS Health Comprehensive Care at Home. Clinical services will include Recovery Care at Home, Rehabilitation Care at Home, Palliative Care at Home, Primary Care at Home and Home Health.

Home health services include skilled nursing care; physical, occupational and speech therapy; medical social work; and home health aides to assist with activities of daily living, such as bathing, dressing and eating. Home health services will operate as UAMS Health Home Health across 12 counties in Central Arkansas.

“Amedisys is proud to partner with UAMS to provide a comprehensive program that will improve the outcomes and experiences for our patients in Central Arkansas,” stated Amedisys Chairman and CEO Paul Kusserow. “Along with Contessa, our partnership allows us to offer the first-of-its-kind model to the region and the first Comprehensive Care at Home program to the state. This also marks the first partnership where Amedisys and Contessa are delivering this integrated model of comprehensive care in the home from the outset – a model we look to provide with other innovative health system partners nationwide.”

“UAMS is leading the ambitious goal of making Arkansas the healthiest state in the region, and this strategic initiative supercharges that vision,” said Cam Patterson, M.D., MBA, UAMS chancellor and CEO of UAMS Health. “We are thrilled to partner with Contessa and Amedisys to bring this first-of-its-kind model to the region and the first Comprehensive Care at Home program to the state. We look forward to giving our patients an innovative option that delivers on our commitment of community-focused, patient-centered care.”

Amedisys’ home health operations now include 353 care centers in 35 states, with an average daily census of approximately 70,000 patients and approximately 11,000 home health employees.

In 2022, Modern Healthcare named Amedisys, Inc. to its prestigious Best Places to Work in Healthcare list for the second consecutive year. Amedisys is the second largest provider of home health care and the third largest provider of hospice care in the United States. As of the October 2022 Home Health Compare release, Amedisys’ Quality of Patient Care (QPC) Star score is 4.44. The Company also provides hospice care, personal care, palliative care and high-acuity care.

Labcorp, a leading global life sciences company announced that it has begun operations at a new, larger anatomic pathology and histology (APH) laboratory in Los Angeles, expanding the company’s global central laboratory capabilities.

Labcorp is investing in its APH services as a key component of its global growth and expansion strategy. The new laboratory is a dedicated Center of Excellence focused on APH laboratory testing solutions. The larger laboratory will expand capabilities, such as digital pathology with the use of artificial intelligence (AI), multiplex immunohistochemistry (IHC) and other innovative technologies supporting clinical trials and precision medicine development.

“Our larger, state-of-the-art laboratory allows us to further advance clinical trials across numerous therapeutic areas like oncology, hemato-oncology and liver disease,” said Vincent Drouillon, senior vice president of global testing services and scientific and medical affairs for Labcorp Drug Development’s Clinical Trial Testing Solutions business. “Additionally, it will enable us to increase capacity and to enhance capabilities of our APH services offering, including exploratory biomarkers, fully validated tests, international quality standards and companion diagnostics.”

Most of the new laboratory space can be reconfigured without construction, enabling fast adjustment for new technologies, spikes in demand and changes in workflow. In addition to the flexibility of design, the new laboratory can also be expanded for future growth.

The Los Angeles facility complements the broader global central laboratory and specialty testing capabilities of Labcorp. Additional global growth includes recent expansions to Labcorp’s APH laboratories in Singapore and Switzerland, as well as the opening of an APH lab section in Japan.

Asieris Pharmaceuticals, a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that Hexvix^®, a drug used for bladder cancer diagnosis, completed dosing for first patient in its real-world clinical study at Hainan General Hospital Lecheng Branch.

Hexvix^® has been approved in the United States and many European countries. The combined use of Hexvix^® and blue light cystoscopy (BLC) for the management of non-muscle invasive bladder cancer (NMIBC) has been included in the global expert consensus guidelines as well as the Chinese Urological Association Guideline.

In January 2021, Asieris Pharmaceuticals entered into a license agreement with Photocure ASA (Photocure, OSE:PHO), a bladder cancer specialty company based in Oslo, Norway, and obtained the exclusive registration and commercialization rights of Hexvix^® in mainland China and Taiwan.

“Thanks to the policies introduced by the Hainan Provincial Government and the Bo’ao Lecheng Pilot Zone of International Medical Tourism, we successfully completed dosing of Hexvix^® for the first patient in our real-world clinical study. By taking advantage of the beneficial policy associated with real-world studies in Hainan, we hope to accelerate the approval of the innovative product Hexvix^® in China to meet the growing medical needs of bladder cancer patients,” said Dr. Zhuang Chengfeng, Chief Operating Officer of Asieris Pharmaceuticals.

Avenda Health, an AI healthcare company creating the future of personalized prostate cancer care, announced its cancer management platform, iQuestTM, has received 510(k) clearance by the U.S. FDA.

iQuest combines existing patient-specific diagnostic information and deep-learning algorithms to create a tailored map of where cancer is within the prostate that for the first time will allow for more personalized, effective and precise treatments. The platform enables a physician to make decisions that consider the cancer extent rather than treating the whole organ. This information supports physicians and patients with treatment selection, planning, guidance, and follow-up.

We are excited about the potential to unlock precision care in prostate cancer with iQuest, as it is a key enabling technology for focal therapy to be a reality for urologists and patients,” said Dr. Shyam Natarajan, co-founder and CEO of Avenda Health. “In order for a doctor to treat focally, they need to know where cancer is and the healthy tissue to avoid. This is vital information that iQuest now provides. This is a huge step forward in transforming the standard of care in prostate cancer and brings us that much closer to offering effective therapy that preserves quality of life to providers and patients across the U.S.”

One in eight men will develop prostate cancer in their lifetime. The current one-size-fits-all approach of treating the entire prostate‒because current MRI technology cannot identify the full extent of the tumor and cancer growth within the prostate‒results in nearly 50 percent of patients losing their sexual or urinary function. iQuest personalizes treatment options for the individual patient in order to preserve quality of life and prevent recurrence. Providing physicians with a 3D visualization of the cancer offers a better understanding of the extent of the disease to aid in treatment planning that can preserve quality of life while minimizing cancer left behind.

iQuest was built upon a decade of research from hundreds of thousands of data points and validated in multiple clinical studies. In one study, urologists improved their sensitivity of identifying tumor extent by using iQuest from 37% to 97% and changed their treatment recommendation in 27% of cases, with the biggest change towards a more localized treatment. iQuest can be applied to multiple treatment options to guide a doctor’s intervention plan, including FocalPoint—Avenda Health’s soft tissue laser ablation device—and other focal treatments, active surveillance, and decision-making for whole gland treatments including radical prostatectomy and radiation therapy.

“At the heart of what we do is the belief that patients should never have to choose between quality of life and cancer control,” said Dr. Brittany Berry-Pusey, co-founder and COO of Avenda Health. “By providing a personalized cancer map, iQuest opens the door for more precise treatments. This clearance will go a long way not only for our company but for the future of prostate cancer care.”

The company recently raised $10M in Series B funding to accelerate the use of iQuest and continue clinical evidence development.

Medical professionals might not seem like the type to require the aid of an experienced attorney, and yet there are a number of instances in which this is necessary.

So if you’re a physician, knowing when to get in touch with a criminal lawyer will save you from all sorts of professional and personal complications. Let’s look at some of the scenarios where it’s wise to call in the legal eagles.

If accused of a crime outside of the office

Most states have strict rules governing the licensing of doctors who want to operate within their borders, and you could struggle to get approved if you either have a historic conviction on your record, or you have a recent accusation of a criminal act that has yet to be settled.

It doesn’t matter whether or not the crime in question is related to your job, as it could still reduce your chances of attaining a license to practice medicine in a given region. So no matter how minor the offense, whether a misdemeanor or a low level felony, it should not be brushed to one side. Instead, working with a lawyer to resolve it will ensure your career is not derailed.

If accused of a crime, e.g. assault, by a patient

Another surprisingly common scenario that doctors can face is having one of their patients level a criminal accusation against them.

This comes with the territory, since every day medical pros interact with people from all walks of life, and when healthcare is being provided for potentially serious conditions both mental and physical, tensions can mount and misunderstandings can occur.

Should a patient accuse you of assault or any other crime, contacting an attorney like those found at https://monmouthcountycriminallawyers.com/ should be a priority.

Because of the difference between state-level laws across the country, it’s important to ensure that the lawyer you pick is a local specialist. That way they’ll have the knowledge and experience of the regional legal system which will deliver the best possible outcome for your case.

Another point to bear in mind that assault charges are fairly broad in terms of the acts they cover. You can be accused of this crime if the threat is purely verbal, and so being clued into the potential for disruption from a patient’s accusation is vital. That way you’ll know how to respond in this instance, rather than being blindside and paralyzed by indecision.

If subjected to criminal actions by a third party, whether a patient or another team member

Doctors won’t only need to hire an attorney when they are on the receiving end of a criminal accusation, because it’s just as possible for a medical pro to be the victim of a crime in the course of achieving patient satisfaction.

There may be the temptation to brush aside aggressive, violent or destructive actions of others, especially if you are the one in the position of giving them care, and thus feel a responsibility to look after them and forgive them for overstepping boundaries due to the power dynamics of this relationship.

However, it can equally be very traumatizing for doctors to go through problematic interactions, whether with patients or with members of staff.

Whether or not you decide to take things further, it is a good idea to contact a criminal lawyer to ask for advice and guidance in this context.

An experienced attorney will be able to talk you through your options, and provide you with the support you need to feel well represented and seen.

The bottom line

Every doctor has the right to defend themselves and protect their professional and personal reputation if accused of a crime.

Equally, we all should take advantage of the legal mechanisms available to us in the case that we fall victim to criminal acts in all their forms.

Working in healthcare puts you in a more precarious position because of the stringent licensing rules, so you cannot afford to be complacent about any accusation.

Moreover, if you find the right lawyer then they will be an invaluable point of contact not just for one incident, but for any other troubles you face over the course of your career.

MindMaze, a global pioneer in the development of AI-driven neurotechnology, and Vibra Healthcare, a leader in post-acute hospital patient care, are excited to announce a partnership to deploy MindMaze’s digital health technology platform (MindPod® and MindMotion®GO) in-clinic and at-home for patients within select Vibra hospitals in Kentucky and California as a first step. MindMaze’s digital neurotherapeutic solutions are designed to help patients regain function through digitally-enabled assessments as well as behavioral training of holistic motor, cognitive and cardiovascular systems following Stroke/TBI, SCI, Parkinsons Disease and other neurological indications. This innovative partnership will enable clinicians to provide patients in the clinic and at home with interventions at dosage and intensity levels that are orders of magnitude higher than the current standard of care.

MindMaze delivers novel software-based interventions and assessments for neurological diseases, as well as capabilities that monitor and measure patient function during the long-term management of chronic disease. The partnership will facilitate a large-scale roll-out of MindMaze solutions to improve care across in-patient, post-acute, community sub-acute and home-based care environments. The goal is to deliver a substantial increase in training and treatment for Vibra’s patients, as well as to offer seamless and coordinated transitions in care as patients are treated within the Vibra Healthcare System which operates and manages over 90 specialty hospitals as well as transitional care units/facilities in 19 states.

The need for solutions that deliver superior outcomes—as well as those that support patients during the lifetime of their chronic condition—has never been greater. Nearly 100 million Americans are afflicted by a neurological disease, as reported in the Annals of Neurology, resulting more often than not in costly disability that can worsen over time. Nearly 50% of the total health burden in the United States is due to morbidity and disability. Consolidated studies have demonstrated that high dose, high intensity training can improve outcomes in traditionally hard-to-treat neurological indications. MindMaze believes that multimodal technology is fundamental to address the growing challenges faced by clinicians, patients and caregivers alike.

“MindMaze is committed to redefining neuro recovery across the continuum of care through the development evidence-driven solutions for patients with serious neurological conditions,” said Tej Tadi, Founder, Chairman & CEO of MindMaze. “We are focused on providing clinicians with powerful, digitally-enabled, cutting-edge tools, while also empowering patients and their families with easy-to-use, engaging and accessible solutions. In Vibra we have found a world-class partner with both the commitment and true capability to deliver a step-change in brain health as well as meaningful improvements in patient outcomes.”

“Vibra is committed to delivering the best possible care for our patients and the best value for our customers,” said Brad Hollinger, Founder, Chairman and CEO of Vibra Healthcare. “Our facilities have consistently ranked among the top-rated hospitals and rehabilitation facilities in the country, and we are always looking for ways to improve upon our incredibly high standards. We strongly believe that innovative technology in AI is the pioneering path forward to dramatically improve patient outcomes in the most cost-effective way. MindMaze has impressed our team not just with the power of their technological capabilities, but also with their experience in deploying real-world care pathways for patients with Stroke and other neurological conditions in countries around the world.”

Kineon introduced a red-light therapy device that uses LED and medical-grade laser technology, that supports the near-complete recovery of damaged blood vessels and cartilage, reduces inflammation and decreases joint pain and strengthens the body’s own unique healing process for faster rehabilitation.

The Move + is a next-generation red light therapy device that uses both LED lights and medical-grade laser technology, to optimize full recovery. For any struggles with joint pain, this device can help with quicker recovery while also restoring damaged tissue. Move+ offers targeted relief to knee pain, helping to reduce inflammation and ease the pain. The Kineon Move+ was designed to solve all of those problems: the wearable device wraps comfortably around your arm or leg, emits laser NIR into internal tissue (which penetrates more effectively than only LED light), and by using three separate laser modules simultaneously internal tissue is treated even more effectively, delivering exactly the right dose with sniper-like accuracy. Better yet, The Move+ uses next-generation Dual-Light Therapy technology, delivering its red light through both medical-grade lasers and LEDs. And this is more effective at reducing pain and inflammation, increasing blood flow, and supporting the near-complete recovery of damaged blood vessels and cartilage.

There are many red-light therapy devices; most commercial ones are ineffective. With light therapy, dosing is as important, or even more so, than pharmaceuticals. Most light therapy products are not designed based on optimal dosing for internal tissue where inflamed, painful tissue needs to be treated. Light therapy panels are comparable to shaking a pill bottle in front of your face and hoping what falls in is the correct dosage. Often, they don’t even deliver the right dosage of red/NIR light, which leads to less-than-optimal results.

These benefits have been validated by a series of clinical studies, including hundreds of human trials. Clinical studies show just how effectively light therapy reduces pain and inflammation. According to Kineon’s Chief Science Officer, Evan Peikon observation, a single 5-minute Move+ session, improved blood flow and vascular health in the treated tissue. Suffering from bone and knee pain is not easy, but the MOVE+ & Science of Light Therapy has put an end to this pain.

HeartBeam, Inc., a cardiac technology company that has developed the first and only 3D-vector electrocardiogram (VECG) platform for heart attack detection anytime, anywhere, announced it has signed an agreement (the “Agreement”) with Evolve Manufacturing Technologies (“Evolve”), a contract medical device manufacturing company, to build the credit card-sized AIMIGo 3D vector electrocardiogram (VECG) recording device that provides a 12 lead ECG readout for remote heart attack detection. Under the terms of the Agreement, HeartBeam will leverage Evolve’s manufacturing and packaging expertise to support commercialization of the HeartBeam AIMIGo device in anticipation of early market testing in Q2 2023 following expected FDA Clearance in early 2023.

HeartBeam has developed a personal, portable and easy-to-use heart attack detection solution that can be used by patients anytime, anywhere to assist patients and their clinicians in assessing whether symptoms may be the result of a heart attack. HeartBeam’s breakthrough solution employs a reusable, credit card-sized, 3D vector ECG recording device and cloud-based software to deliver critical data to clinicians in real-time outside of a medical setting. More than 18 million people in the U.S. have coronary artery disease, and every 40 seconds someone in the U.S. has a heart attack.

As Silicon Valley’s premier medical device manufacturer, Evolve provides end-to-end contract manufacturing for medical device and life sciences instrument companies. Coupled with best-in-class guidance and attention along with proven quality processes, Evolve offers ISO-certified turnkey contract manufacturing for medical device companies. Evolve has previously collaborated with Triple Ring Technologies, HeartBeam’s co-developer of the AIMIGo device, creating additional synergies as the device moves into manufacturing technology transfer.

“Evolve has deep medical device manufacturing expertise and a strong reputation in the industry for delivering consistent product quality and customer care rarely found in medical contract manufacturers,” said Branislav Vajdic, PhD, CEO and Founder of HeartBeam. “Evolve’s dedicated customer teams use Design for Excellence (DFX) methodologies, and state-of-the-art, end-to-end quality processes, plus world-class materials suppliers to ensure consistent and high-quality products. We have now begun technology transfer from Triple Ring Technologies to Evolve as they develop and obtain experience with our product in preparation for manufacturing.

“With our successful five-phase device technology development project with Triple Ring nearing completion, we are advancing towards pre-commercial production. We believe Evolve’s long standing collaborative relationship with Triple Ring will greatly benefit HeartBeam in expediting technology transfer through commercial production once we have received FDA clearance for AIMIGo, estimated for the first quarter of 2023,” concluded Dr. Vajdic.

“Evolve is excited to partner with HeartBeam to manufacture the integral medical device that is part of their AIMIGo solution for detecting heart attacks outside of a medical setting,” said Noreen King, CEO of Evolve Manufacturing Technologies. “We look forward to providing our manufacturing expertise to the HeartBeam team to help turn their innovative science into a commercial product.”